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PENILAIAN TERHADAP INTERAKSI DRUG PENTING YANG 
MELIBATKAN PERENCAT PENUKAR ENZIM ANGIOTENSIN  
DIKALANGAN PESAKIT JANTUNG 
 
 
ABSTRAK 
 
 
Perencat penukar enzim angiotensin (ACEIs) telah digunakan secara meluas untuk 
merawat hipertensi dan penyakit kardiovaskular yang lain. Interaksi ubat-ACEI 
adalah merupakan masalah kesihatan yang signifikan dan perlu penyelidikan lanjut. 
Penyelidikan ini dijalankan bertujuan untuk menilai kesan interaksi ubat-ACEIs 
termasuk hiperkalemia, nefrotoksisiti, hipotensi ortostatik dan penurunan 
keberkesanan ACEIs. Satu kajian prospektif kohort telah dijalankan untuk 
mengenalpasti insidens, kebarangkalian, keterukan kesan-kesan tersebut dan faktor-
faktor risiko yang terlibat.  Persampelan mudah dilakukan ke atas 500 orang pesakit 
jantung dewasa yang telah menerima rawatan ubat ACEIs bersama dengan ubat-
ubatan lain di wad perubatan dan kardiologi, Hospital Pulau Pinang dari Januari 
hingga Ogos 2006. Data ciri-ciri demografi, tanda-tanda vital, komobiditi, terapi ubat 
terkini, dan ujian-ujian makmal telah dikumpulkan. Penilaian susulan keadaan 
pesakit dipantau untuk menilai sekiranya terdapat kesan dan/atau simptom yang 
berkaitan interaksi ubat dengan agen ACEIs. Hiperkalemia ditakrif berdasarkan paras 
kalium serum melebihi 5 mmoL/L dan nefrotoksisiti dinilai sekiranya paras urea 
serum melebihi 8.3 mmol/L dan kreatinin serum melebihi 130µmol/L. Sementara itu, 
purata tekanan arteri (MAP) yang kurang daripada 80 mmHg diguna sebagai definisi 
hipotensi ortostatik. Penurunan kesan ACEIs didefinisikan sebagai kegagalan untuk 
mencapai matlamat terapi ACEIs dan penilaiannya dibuat menggunakan terminologi 
status hasil farmakoterapi. Skala Kebarangkalian Interaksi Ubat (Drug Interaction 
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Probability Scale DIPS) digunakan untuk menilai kebarangkalian hubungan di antara 
interaksi ubat dengan kesan buruk. Ujian ‘Mann-Whitney’ dan ujian t yang tidak 
bersandar digunakan untuk membandingkan nilai purata sekiranya perlu. ‘Binary 
Logistic Statistic’ digunakan untuk analisis univariat manakala ‘backward stepwise 
logistic regression’ digunakan untuk analisis multivariat. Keputusan kajian 
menunjukkan insidens kesan buruk  tersebut adalah hiperkalemia, 9.8%; 
nefrotoksisiti, 8.4%;hipotensi ortostatik, 8.2%; dan penurunan efikasi ACEIs, 1.6%. 
Kebarangkalian hubungan keempat-empat kesan buruk tersebut dengan interaksi 
ubat-ACEIs adalah berjulat diantara perkadaran mungkin dengan paling mungkin. 
Keterukan kesan buruk berada di antara perkadaran major dengan minor untuk 
hiperkalemia, manakala untuk lain-lain kesan buruk berada di antara sederhana 
dengan minor. Usia yang lanjut (≥ 60 tahun), penyakit hepar dan ginjal, dan jumlah 
ubat-ubatan merupakan faktor-faktor risiko yang meningkatkan risiko untuk 
hiperkalemia. Tabiat merokok, penyakit hepar dan jumlah ubat-ubatan merupakan 
penentu yang menyumbang kepada peningkatan risiko nefrotoksisiti. Penyakit hepar 
dikenalpasti sebagai penyebab yang singnifikan untuk hipotensi ortostatik. Kajian ini 
telah mengenalpasti interaksi ubat ACEIs di kalangan pesakit jantung yang 
signifikan secara klinikal. Penyakit hepar didapati sebagai faktor penting yang 
mengaruhkan hiperkalemia, nefrotoksisiti dan hipotensi ortostatik. Perhatian khusus 
disarankan untuk pesakit yang menerima bersama ubat yang dapat berinteraksi 
dengan ACEIs. 
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EVALUATION OF CLINICALLY IMPORTANT DRUG INTERACTIONS 
INVOLVING ANGIOTENSIN-CONVERTING ENZYME INHIBITORS 
AMONG CARDIAC PATIENTS 
 
 
ABSTRACT 
 
 
Angiotensin-converting enzyme inhibitors (ACEIs) are widely used for the treatment 
of hypertension and other cardiovascular diseases. ACEIs-drug interaction is a 
significant health problem that needs further investigations. This research aimed to 
evaluate adverse events of ACEIs-drug interactions including hyperkalemia, 
nephrotoxicity, orthostatic hypotension and reduced efficacy of ACEIs. A 
prospective cohort study was conducted to identify the incidence, probability and 
severity of such events and also to determine the associated risk factors. Using 
convenient sampling, 500 adult cardiac patients admitted to medical and cardiology 
wards at Penang Hospital, who received ACEIs concomitantly with interacting 
drugs, were recruited from January to August 2006. Data on demographic 
characteristics, vital signs, comorbid conditions, current drug therapies, and 
laboratory investigations were collected. Patient’s follow-up evaluation was done for 
any signs and/or symptoms of adverse events associated with ACEIs-drug 
interactions. Hyperkalemia was defined as potassium level above 5.0 mmol/L and 
nephrotoxicity as serum urea and creatinine above 8.3 mmol/L and 130 µmol/L, 
respectively. Mean arterial pressure (MAP) of less than 80 mmHg was used to define 
orthostatic hypotension. Reduced efficacy of ACEIs was defined as the failure to 
achieve the goal of ACEIs therapy and its evaluation was made using 
Pharmacotherapy Outcomes Status Terminology. Drug Interactions Probability Scale 
(DIPS) was used to assess the likelihood of association between the drug interactions 
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and the events. Mann-Whitney test and independent t-test were used to compare 
means wherever applicable. Binary logistic statistics were used for univariate 
analyses, whereas, backward stepwise logistic regression was used for multivariate 
analyses. This study showed that the incidences of the events were: hyperkalemia, 
9.8%; nephrotoxicity, 8.4%; orthostatic hypotension, 8.2%; and reduced efficacy of 
ACEIs, 1.6%. Probability of association of the four events with ACEIs-drug 
interactions ranged between probable and possible rating. The Severity was found 
between major and minor rating for hyperkalemia, whereas, it was rated between 
moderate and minor for other events. Advanced age (≥ 60 years), renal and hepatic 
disease and number of medications were risk factors associated with increased risk of 
hyperkalemia. Smoking habit, hepatic disease and number of medications were 
predictors that contributed to high risk of nephrotoxicity. Hepatic disease was 
considered as a significant predictor for orthostatic hypotension. This study has 
identified clinically important ACEIs-drug interaction events among cardiac patients. 
Hepatic disease was found as an important factor that predicts hyperkalemia, 
nephrotoxicity and orthostatic hypotension. Special attention for patients who are 
prescribed ACEIs with interacting drugs is strongly recommended. 
 
 
 
CHAPTER 1 
    INTRODUCTION 
 
1.1 Background 
A drug interaction is an interference of a drug with the effect of another drug, food or 
drugs in clinical laboratory tests or diseases. Drug-drug interactions (DDIs) are 
considered as a situation in which the effects of one drug are altered by prior or 
concurrent administration of another drug (Gennaro et al., 2000). DDIs are important 
subsets of adverse drug events. There is focusing attention on the prevention of DDIs 
to reduce errors in the administration of prescribed medications. However, adverse 
drug reactions (ADRs) including drug interactions are defined according to World 
Health Organization (WHO) (1972, cited by Linda and Colleen,1991) as a noxious 
and unintended response that occurs at doses normally used in man for the 
prophylaxis, diagnosis or therapy of a disease, or for the modification of 
physiological functions. 
 
1.1.1 Mechanisms of drug interactions 
Mechanisms of drug interactions are classified as pharmacokinetic and 
pharmacodynamic interactions.  
 
1.1.1 (a) Pharmacokinetic interaction 
It occurs when the precipitant (interacting) drug alters the absorption, distribution, 
metabolism or elimination of object drug leading to change of plasma concentration 
of the later drug (Gennaro et al., 2000).    
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Moreover, pharmacokinetic drug interactions are often manageable and their risk can 
be reduced by dosage adjustments  (Bergk et al., 2004). 
 
1.1.1(b) Pharmacodynamic interaction 
This type of interaction occurs when the drug has similar or opposite 
pharmacological effects to the object drug when administered concurrently, leading 
to a change in pharmacological effect by additive (synergistic) effect or opposite 
(antagonistic) effect without change in drug plasma concentration (Gennaro et al., 
2000). Notably, pharmacodynamic interactions are exclusively relevant to the elderly 
patients because the elderly patients have reduced homeostatic mechanisms 
(Seymour and Routledge, 1998).  
 
1.1.2 Causes of drug interactions 
In accordance with the suggestion of Moini (2005), there are many causes of drug 
interactions including multiple pharmacological effects, non-prescription drug use, 
patients’ non-compliance and drug abuse. 
 
1.1.3 Risk factors for drug interactions  
Patient-related risk factors for drug interactions include age, sex, genetic factors, 
predisposing diseases and lifestyle such as smoking and alcohol consumption  (Bergk 
et al., 2004). A study by Bjerrum et al. (2003) demonstrated that one third of the 
study population had received two or more drugs. Of these only 15% were exposed 
to drugs with potential interaction and the risk of interaction increased with age. 
Moreover, they observed that most interactions were found in patients treated with 
cardiovascular drugs such as diuretics, angiotensin-convering enzyme inhibitors 
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(ACEIs), digoxin, beta blockers and calcium channel blockers with non steroidal 
anti-inflammatory drugs (NSAIDs), antidiabetics, potassium-sparing diuretics and 
anticoagulants. 
 
Patients taking multiple drugs usually have multiple diseases. Therefore, their ability 
to metabolize the drugs can be affected as a result of target organs that are more 
sensitive to the effects of the drug (Leipzig and Edelberg, 2001). Hence, adverse drug 
reactions are higher in geriatric patients who receive large number of drugs (Egger et 
al., 2003a). A study conducted in Colorado by Page ІІ and Ruscin (2006) 
documented that a higher number of admission medications (≥ 5) was strongly 
associated with adverse drug events in hospitalized elderly patients. Similarly, a 
study carried-out by Straubhaar et al. (2006) showed that the number of medications 
and the number of potential DDIs per patient significantly increased during hospital 
stay.  
 
Despite accumulating evidences that using multiple drugs to treat many diseases of 
the elderly decreases morbidity and mortality, the potential for clinically significant 
drug interactions greatly increased (Delafuente, 2003). A retrospective study 
performed in Thailand found that the rate of potential drug interactions was directly 
proportional to the patient’s age and the number of the drugs they received 
(Janchawee et al., 2005). 
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1.1.4 Epidemiology of drug interactions 
Most published studies used different methods and criteria to define and distinguish 
between clinically significant and clinically non-significant drug-drug interactions. 
Therefore, it is difficult to obtain an accurate estimate of the incidence of drug 
interactions (Boxtel et al., 2001).   
 
Harvard Medical Practice Study I, carried-out by Brennan et al. (2004) found that the 
incidence rate of adverse drug events in hospitalized patients was 3.7% of hospital 
inpations. Whereas, Bates and colleagues (1993) noted that the incidence of adverse 
drug events was about six per 100 admissions. In a population-based study conducted 
in Utah and Colorado, 0.63% was the incidence of preventable adverse drug events 
among elderly inpatients (Thomas and Brennan, 2000). 
 
A previous study showed that more than one-half of hospitalized patients who were 
exposed daily to eight drugs were receiving potentially interacting drugs (Bente et 
al., 2005). Whilst, potentially serious drug interactions were found in 1.4% of the 
prescriptions and 7.4% of the patients who had been prescribed concurrently two or 
more drugs (Grönroos et al., 1997). Björkman et al. (2002) documented that potential 
DDIs were widespread among elderly patients who received combination of many 
drugs and 50% of the potential DDIs would lead to adverse drug reactions and 
another 50% could reduce therapeutic efficacy. 
 
Egger et al. (2003b) showed in a study conducted at the University Hospital Basel 
that 53.8% of potential drug interactions at discharge resulted from change of 
medications during hospital stay. Moreover, the same study showed that 12.2% of 
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DDIs were classified as major severity and majority of these (63%) were due to 
combination of ACE inhibitors with potassium-sparing diuretics or potassium 
supplementation. 
 
The incidence of DDIs in hospitalized patients ranged between 15-16.6% (Passarelli 
et al., 2005; Pirmohamed et al., 2004). A study conducted in a community and 
general hospital in Los Angeles found that 47% of the study population had been at 
high risk for drug interactions, particularly patients who had received 3 or more 
medications and/or patients older than 50 years of age (Goldberg et al., 1996).  In 
Brazil, Cruciol-Souza and Thomson, (2006), by using a computer program found that 
almost 50% of the prescriptions reported at least one DDI. 
 
A retrospective study noted that the incidence of potential adverse interactions in 
emergency department was 3.8% (Heininger-Rothbucher et al., 2001). Conversely, 
other reports found that the frequency of drug interactions requiring emergency 
department visits ranged from 0.054 to 4% (Raschetti et al., 1999; Becker et al., 
2006). A review of nineteen DDIs studies found a wide variation of reported 
potential drug interactions of clinical significance ranging from 1% to 23.2% (Jankel 
and Speedie, 1990). The review showed that the rates of potential drug interactions in 
hospital patients ranged from 2.2% to 30%. However, the variation in the reported 
incidence rates for all potential drug interactions ranged from 2.2% to 70.3% (Jankel 
and Speedie, 1990).  
 
Drug interaction studies demonstrated five to seven-fold difference in the effect 
between participants. These significant variations might be due to different doses, 
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routes of administration, formulations and sequences of drug administration, genetics 
and other modifiers of drug elimination or response such as food, environment and 
disease (Horn and Hansten, 2004b). 
 
1.1.5 Evaluation and recognition of drug interactions 
The assessment of clinical relevance of a potential DDI requires the knowledge of 
how often a potential DDI indeed clinically manifests (Egger et al., 2003b). A study 
conducted at University of Erlangen showed that 18% of hospitalized patients 
experienced probable or definite adverse drug reactions that could have been 
detected from abnormal laboratory tests  (Tegeder et al., 1999). Nevertheless, only 
about one-third were detected and treated by physicians (Tegeder et al., 1999). In 
contrast, a study suggested that computerized algorithms may support physicians but 
never replace the comprehensive clinical evaluation of the individual case (Bergk et 
al., 2004). Furthermore, another report showed a limited use of computerized drug 
database in monitoring elderly patients  (Egger et al., 2003a). Notably, a prospective 
case series study was conducted to evaluate a computer alert system used to detect 
adverse events. They found that only one patient presented with serious potential 
consequences of positive alert; an elderly patient with renal insufficiency and 
hyperkalemia due to receiving ACEIs and potassium chloride (Raschke et al., 1998). 
 
According to Linda and Colleen (1991), the recognition of adverse drug reactions or 
interactions requires physician’s review of patient’s clinical course, observation of 
relevant characteristics of patient and drug reaction outcome. However, for the 
assessment of the probability of association of the drug and drug reactions, patient’s 
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current medications, significant medical problems and risk factors for drug 
interactions should be evaluated (Linda and Colleen, 1991). 
 
1.1.6 Management of drug interactions  
The identification of patients at risk and an accurate management of their drug 
therapy are important challenges for health care professionals to avoid serious 
clinical consequences caused by adverse drug reactions (Indermitte, 2006). 
Moreover, a complete medication history of prescribed and non-prescribed drugs 
taken by patients is an essential consideration to avoid or minimize drug interactions 
risks (Moini, 2005). 
 
Management of DDIs can be through proper dosage adjustment of the interacting 
drugs or prescription of non-interacting combination drugs. The interaction can be 
managed by close laboratory or clinical monitoring for evidence of interaction 
(Hansten, 2003). However, drug interactions sometimes might be predictable, 
depending on the knowledge of pharmacological properties of the drugs and 
understanding of pharmacokinetic and pharmacodynamic principles of the 
combination drugs (Moini, 2005). 
 
1.2 ACE inhibitors  
 
1.2.1 Renin system 
The renin-angiotensin-system (RAS) plays a major role in the development and 
progression of cardiovascular diseases. Angiotensin-converting enzyme (ACE) is an 
enzyme involved in the metabolism of many small peptides including the conversion 
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of angiotensin I, an inactive octapeptide into angiotensin II (Lopez-Sendon et al., 
2004). RAS has a pivotal role in blood pressure regulation. Reducing sodium 
delivery at macula densa, decrease renal perfusion pressure, and sympathetic 
activation, all these lead to stimulation  of renin secretion by the juxtaglomerular cell 
(Brown and Vaughan, 1998). 
 
 ACE also known as kininase II, is the enzyme that catalyses the degradation of 
bradykinin and other potent vasodilator peptides (Lopez-Sendon et al., 2004). Kinins 
exert vasoactive effects by releasing various autocoids from endothelium. Activation 
of endothelial bradykinin receptors increases the formation of local vasodilators 
nitric oxide (NO), which is known as endothelium-derived relaxation factor, 
epoprostenol known as (prostacyclin, prostaglandin I2) and platelet-activating factor 
(Verme-Gibboney, 1997). In addition, ACE controls the balance between the 
vasodilatory and natriuretic effect of bradykinin as well as vasoconstrictive and salt-
retentive properties of angiotensin II.  ACE inhibitors alter this balance by decreasing 
the formation of angiotensin II and the breakdown of bradykinin (Brown and 
Vaughan, 1998). 
 
Angiotensin II is the main effector molecule of RAS that can act either as systemic 
hormone (endocrine) or as a locally generated factor (paracrine, autocrine) (Unger, 
2002). Moreover, angiotensin II is a hormone circulating in the blood and has crucial 
roles in cardiovascular systems. Its key function is to constrict blood vessels leading 
to elevation of the blood pressure and increasing the work required for the heart to 
pump blood into systemic circulation. This effect is critical for weakened heart 
muscle in case of heart attack or heart failure (Sweitzer, 2003). 
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Angiotensin II has a significant role in the pathophysiology of heart failure. 
However, there is a controversy that another enzyme in addition to ACE could 
contribute to local production of angiotensin II in the heart. This is known as 
chymase, a chymotrypsin-like serine protease that is synthesized and stored in the 
cardiac mast cells and is not affected by ACE inhibitors. Chymase exerts its action 
on the heart after the mast cells are stimulated to degranulate in chronic 
inflammatory states  (Kokkonen et al., 2003).  
 
It is worthwhile to note that, angiotensin II plays a negative role in growth promotion 
by increasing the size and thickness of several cardiovascular structures. High level 
of angiotensin II in the blood leads to thickening of the heart which is known as 
hypertrophy and it is recognized as a sign of high risk of death caused by heart 
disease (Sweitzer, 2003). Moreover, elevation of angiotensin II level in the walls of 
blood vessels triggers it to become thicker and stiffer. In addition to the constriction, 
the arteries become predisposed to cholesterol deposits and blockages which can lead 
to heart attacks and strokes  (Sweitzer, 2003). 
 
1.2.2 Role of ACE inhibitors in cardiovascular diseases 
The cardioprotective actions of ACE inhibitors occur by increasing the oxygen 
supply to tissue oxygen demand during various cardiovascular stresses. The 
beneficial cardiovascular effects of ACE inhibitors in addition to its hemodynamic 
action are related to an improvement of the cardiovascular kinin/nitric oxide (NO) 
pathway (Magen and Viskoper, 2000). 
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ACE inhibitors attenuate the formation of angiotensin II by competitively blocking 
the conversion of angiotensin I to angiotensin II, thereby, reducing the circulation 
and local levels of angiotensin II. Also it reduces aldosterone and vasopressin 
secretion and decreases sympathetic nerve activity (Lopez-Sendon et al., 2004). 
However, a study suggested that the most important vascular effect of ACE 
inhibitors is related to accumulation of endogenous bradykinin rather than due to 
reduced generation of angiotensin II (Hornig et al., 1997). This occurs by ACE 
inhibitors’ enhancement effect on flow-dependent, endothelium-mediated dilation by 
a bradykinin-dependent mechanism (Hornig et al., 1997). Furthermore, ACE 
inhibitors decrease the total peripheral vascular resistances, promote natriuresis and 
cause little change in heart rate. Also it has little effect on cardiac output or capillary 
wedge pressure in normotensive and hypertensive patients without chronic heart 
failure (Lopez-Sendon et al., 2004). 
 
Activation of RAS may exert many adverse effects on the cardiovascular system 
such as arterial hypertension, chronic renal failure and atherosclerosis (Grote et al., 
2004). More evidences indicate that the RAS not only plays a role in development of 
cardiac remodeling and heart failure, but also it has a role in initiation and 
progression of aspects of cardiovascular disease including atherosclerosis (Schmidt-
Ott et al., 2000). Similarly, an experimental study documented a pathogenic role for 
the RAS in early stages of atherosclerosis. Therefore, the RAS play an important role 
in both initiation and acceleration of atherosclerotic process and ACE inhibitors may 
have benefit in treatment of this disease (Warnholtz et al., 1999). 
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ACE inhibitors are a cornerstone therapy for heart failure patients with left 
ventricular systolic dysfunction. However, diuretics are essential for controlling 
volume overload, but they do not confer mortality reduction benefits like the first-
line therapies of ACE inhibition and beta blockade (Bicket, 2002), except 
spironolactone which can reduce mortality from progressive heart failure  (Pitt et al., 
1999). The Heart Outcomes Prevention Evaluation (HOPE) study showed that the 
use of long-acting ACE inhibitors in patients with normal left ventricular function 
and no evidence of heart failure who are at high risk for cardiovascular disease could 
reduce rates of mortality, myocardial infarction, stroke, coronary revascularization, 
cardiac arrest and heart failure. Moreover, ACEIs may reduce the risk of diabetes and 
relevant complications (The Heart Outcomes Prevention Evaluation (HOPE) Study 
Investigators, 2000). However, evidences suggested that ACE inhibitors should be 
initiated early and continued for years in patients with heart failure and/or left 
ventricular dysfunction following myocardial infarction (Bonarjee and Dickstein, 
2001). 
 
1.2.3 Role of ACE inhibitors in renal diseases 
Clinical evidences suggested that the use of drugs that block RAS are beneficial for 
patients with renal insufficiency (Bakris and Weir, 2000). Moreover, as cited by 
Bakris and Weir (2000) in accordance with the Sixth Report of The Joint National 
Committee on Prevention, Detection, Evaluation and Treatment of High Blood 
Pressure (JNC VI, 1997), that ACEIs are specifically indicated for use in patients 
with renal insufficiency [i.e. serum creatinine 133-265 µmol/L (1.5-3.0 mg/dL)] 
(Bakris and Weir, 2000). However, when ACEIs are used with antihypertensive 
therapy, they demonstrate therapeutic benefits and provide renoprotective effects that 
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 The intrinsic renal autoregulation mechanism is adjusted by two mechanisms, 
angiotensin II and the sympathetic hormones. The decline or fall of renal perfusion 
pressure in case of hypovolemia or chronic heart failure, leads to activation of 
sympathetic nervous system and secretion of renin from juxtaglomerular cells of 
afferent arterioles. This further leads to production of angiotensin II at the level of 
renal glomerulus which causes vasoconstriction of postglomerular efferent more than 
preglomerular afferent arterioles. This imbalance of effect on the efferent arteriolar 
circulation restores glomerular capillary pressure and maintains glomerular filtration 
despite reduced perfusion pressure. At this juncture, filtration fraction (glomerular 
filtration rate (GFR)/renal plasma flow) increases, which sustains proximal tubular 
sodium reabsorption (Schoolwerth et al., 2001). Inhibition of these two hormones by 
using ACEIs or NSAIDs leads to reduction of the blood flow and pressure within the 
glomeruli which causes decrease glomerular filtration rate and a rise in serum 
creatinine with resultant functional renal insufficiency (Packer, 1988). The 
progression of renal insufficiency in chronic heart failure patients receiving ACEIs 
becomes acute in the presence of concomitant NSAIDs therapy and the risk of renal 
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 The investigators of Ramipril Efficacy In Nephropathy (REIN) study reported that 
prolongation of ACEIs use for the treatment of patients with chronic proteinuric 
nephropathies significantly delayed the acceleration of end stage renal failure 
(Ruggenenti et al., 1999). Likewise, a study performed in China showed that the use 
of benazepril with conventional antihypertensive treatment, for non-diabetic patients 
with advanced renal insufficiency granted the elevation of renal protection  (Hou et 
al., 2006). Although ACEIs therapy reduces the rate of progressive renal injury in 
renal disease and also improves renal blood flow and sodium excretion rate in 
chronic heart failure, its use is associated with functional renal insufficiency and/or 
hyperkalemia  (Schoolwerth et al., 2001). 
 
A retrospective cohort study performed in an acute care setting found that the 
therapeutic benefits of ACEIs for patients with elevated serum creatinine levels had 
greater increase in survival for patients who had insufficient renal function than 
patients who had normal renal function (Frances et al., 2000). In addition, they 
suggested that moderate renal insufficiency could not be considered a 
contraindication to the use of ACEIs therapy for patients who have poor left 
ventricular ejection fraction following myocardial infarction  (Frances et al., 2000). 
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1.2.4 Pharmacokinetics and pharmacodynamics of ACE inhibitors  
ACEIs are increasingly recognized as having an important role in the treatment of 
hypertension and/or other cardiac, renal and vascular diseases. ACEIs are available 
as ester prodrugs to improve gastrointestinal absorption of the active metabolites of 
most of ACEIs (Edling et al., 1995). They are mostly eliminated via renal excretion 
and some are eliminated by renal and hepatic mechanisms. Thus, the dose of ACEIs 
must be adjusted for patients with renal or hepatic dysfunction, because their active 
metabolites may accumulate in these patients with prolonged use (Verme-Gibboney, 
1997). 
 
ACEIs are classified into three groups according to the chemical structure of their 
active moiety. Sulfhydryl containing ACE inhibitors include captopril, fentiapril, 
pivalopril, zofenopril, benazepril and alacepril. While, fosinopril is the only ACE 
inhibitor drug containing phosphinyl group active moiety. Carboxyl moiety 
containing ACE inhibitor drugs include enalapril, cilazapril, spirapril, lisinopril, 
quinapril, ramipril, trandolapril, moexipril and perindopril (Brown and Vaughan, 
1998; Lopez-Sendon et al., 2004). 
 
It is noteworthy that the doses of ACE inhibitors prescribed in clinical practice are 
considerably lower than the target doses used in randomized clinical trials. However, 
a study suggested that it might be that the higher doses were not achieved because of 
uncertainty about who was responsible for titrating the doses, the hospital clinicians 
or the general practitioners. However, there were possibilities that the doses differed 
for different indications (Kvan and Reikvam, 2004). 
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The oral bioavailability of ACEIs drugs ranges from 13-95%. However, the 
concurrent administration of food adversely affects the oral absorption of ACEIs 
(Harrold, 2006). The three most lipophilic compounds are trandolapril, quinapril and 
benazepril. Whereas, the least hydrophilic compounds are lisinopril, enalapril and 
captopril. Table1.1 demonstrates the pharmacokinetic parameters and standard 
dosages of ACEIs. Renal elimination is the most important route of elimination of 
these drugs. Some of the drugs are renally/hepatically eliminated, whereas others are 
eliminated via renal/fecal route. Moreover, all ACEIs have similar duration of action, 
onset of action and dosing interval, except captopril that has a more rapid onset of 
action and shorter duration (Harrold, 2006). Hence, it requires more frequent dosing 
than other ACEIs. Additionally, perindopril has longer elimination half-life time than 
others ACEIs. 
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Table 1.1 Pharmacokinetic parameters of ACE inhibitors  
 
 
Drug name 
generic/brand 
 
Standard   
dosage* 
(mg) 
 
Onset 
of action 
(hr) 
 
Duration 
of action 
(hr) 
 
Elimination* 
half-life 
(hr) 
 
Route of 
elimination 
 
Captopril 
 Capoten® 
 
Benazepril 
  Lotensin® 
 
Fosinopril 
  Monopril® 
 
Enalapril 
  Vasotec® 
 
Lisinopril 
  Zestril® 
 
Quinapril 
  Accupril® 
 
Ramipril 
  Altace® 
 
Trandolapril 
  Mavik® 
 
Moexipril 
  Univasc® 
 
Perindopril 
  Aceon® 
 
25-100 
t.d.s 
 
2.5-20 
b.i.d 
 
10-40 
daily 
 
2.5-20 
b.i.d 
 
2.5-10 
daily 
 
10-40 
daily 
 
2.5-10 
daily 
 
1-4 
daily 
 
7.5-30 
daily 
 
4-8 
 daily 
 
0.25-0.50 
 
 
1 
 
 
1 
 
 
1 
 
 
1 
 
 
1 
 
 
1 
 
 
0.5-1.0 
 
 
1 
 
 
1 
 
6-12 
 
 
24 
 
 
24 
 
 
24 
 
 
24 
 
 
24 
 
 
24 
 
 
24 
 
 
24 
 
 
24 
 
2 
 
 
11 
 
 
12 
 
 
12 
 
 
12 
 
 
2-4 
 
 
8-14 
 
 
16-24 
 
 
16-24 
 
 
>24 
 
Renal 
 
 
Renal/hepatic 
 
 
Renal/hepatic 
 
 
Renal 
 
 
Renal 
 
 
Renal /fecal 
 
 
Renal/fecal 
 
 
Renal/fecal 
 
 
Renal/fecal 
 
 
Renal 
 
(Harrold, 2006; *Lopez-Sendon et al., 2004) 
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1.3 ACE inhibitors-drug interactions 
Drug-drug interactions are one of the causes of adverse drug reactions in hospitalized 
patients. Numerous DDIs have been reported, but only a few of them are clinically 
significant and merit attention. 
 
Concurrent use of ACEIs with some drugs may lead to drug interactions. However, 
majority of DDIs involving ACEIs are not well understood, but they seemed to occur 
through a combination of both pharmacodynamic and pharmacokinetic mechanisms 
(Anderson and Nawarskas, 2001). Concurrent use of antacids with ACEIs may 
reduce the availability of the ACEIs. Potassium-sparing diuretics and potassium 
supplements or low salt substances with high potassium contents may induce 
hyperkalemia (Lopez-Sendon et al., 2004). Moreover, increased risk of hyperkalemia 
due to coadministration of trimethoprim-sulfamethoxazole with ACEIs in the 
presence of renal impairment or diabetes mellitus has been reported (Hansten and 
Horn, 2005). 
 
Haloperidol may increase the risk of hypersensitivity to ACEIs (Lopez-Sendon et al., 
2004). High incidence of acute renal failure (ARF) was found in patients without 
renal artery stenosis who received ACEIs combined with diuretics (Bridoux et al., 
1992). Furthermore, according to Hansten and Horn (1999, cited by, Anderson and 
Nawarsk, 2001), concomitant use of aspirin with ACEIs probably antagonizes ACEIs 
effects, but this interaction may become less prominent with lower aspirin doses. 
Some evidences suggested that salicylate might reduce the effectiveness of ACEIs in 
congestive heart failure patients (Lopez-Sendon et al., 2004). Similarly, Hansten and 
Horn, (2005) noted that aspirin can inhibit both the antihypertensive effect of ACEIs 
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and other favorable hemodynamic effects in CHF patients. However, the inhibitory 
effect of aspirin is probably dose-related. 
 
Moreover, use of ACEIs with α-blockers such as doxazosin, prazosin and terazosin 
can augment the first-dose syncope (Lopez-Sendon et al., 2004). Further, use of loop 
diuretics with ACEIs may potentiate acute hypotension in the presence of volume 
depletion. Concurrent use of ACEIs with lithium and digoxin may lead to elevation 
of plasma levels of lithium and digoxin (Lopez-Sendon et al., 2004). NSAIDs and 
cyclosporine with ACEIs may increase urea or creatinine levels excessively. 
Furthermore, coadministration of diuretics with ACEIs increases sensitivity to 
vasodilator effects of ACEIs (Lopez-Sendon et al., 2004).  
 
The evaluation of drug interactions requires the knowledge of the onset of the event 
and if the interaction is a known interactive property of the object and precipitant 
drugs (Limon, 2000 ). There is also the need for recognition of any other cause of the 
event, rather than the drug interaction. The recognition of the clinical significance of 
the interaction event, evaluation of the clinical changes and management of the 
interaction are important issues (Limon, 2000). 
 
The likelihood of the relevance or association of the drug interaction event with the 
drug therapy is classified as definite, probable, possible or doubtful (Linda and 
Colleen, 1991). The probability classification is based on the temporal relationship 
between the drug administration and the reaction, whether the reaction is a known 
consequence of the drug, if the reaction were resolved on discontinuation of the drug 
to determine its association with a reaction and if the patient’s clinical state could 
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explain the reaction. Clinical decision sometimes is important to determine 
probability. The Naranjo algorithm is a method for scoring reaction characteristics 
and is frequently used in clinical practice (Linda and Colleen, 1991; Naranjo et al., 
1981).  
 
A study showed that the prevalence of hyperkalemia during a two-year period of 
ACEIs use was 11% (Reardon and MacPherson, 1998). However, a previous study 
found that about 20.5% of the patients exposed to potential DDIs might experience 
hyperkalemia (Straubhaar et al., 2006).  A case-control study of chronic heart failure 
patients showed that hyperkalemia was reported in about 8.5% of hospitalized 
patients (Ramadan et al., 2005). While, the result of a study conducted by Egger et 
al. (2003b) reported that the rate of hyperkalemia due to combination of ACEIs with 
potassium-sparing diuretics was 5.2%. 
 
A study performed among elderly patients with congestive heart failure found that 
the rate of renovascular disease due to ACEIs’ use was 33.7% (MacDowall et al., 
1998). Whereas, a prospective study showed that the incidence rate of treatment-
related acute renal failure (ARF) in elderly was 1.4% (Kohli et al., 2000).  
 
A study in geriatric patients found that the prevalence of orthostatic hypotension due 
to lisinopril use was 60% (Poon and Braun, 2005). Similarly, another study found 
that the prevalence of orthostatic hypotension among elderly patients was 30% 
(Luukinen et al., 1999). The incidence of drug-induced orthostatic hypotension was 
1.3% and mostly occurred in elderly patients (Montastruc et al., 1997). Another 
study showed that the incidence of orthostatic hypotension in hypertensive patients 
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was 27% while in normotensive patients the incidence was 22% (Masuo et al., 1996). 
Egger and colleagues (2003b) documented that the incidence of hypotension due to 
potential DDIs of combination of ACEIs with diuretics was 13.2%. The same 
investigators reported that combination of aspirin with ACEIs decreased 
antihypertensive effect of ACEIs in 10% of the patients, which was considered as 
moderately severe interaction. Moreover, decrease and normalization of blood 
pressure (BP) by antihypertensive drugs such as β-blockers, ACEIs and calcium 
antagonists lead to decreased incidence of orthostatic hypotension in hypertensive 
elderly patients (Masuo et al., 1996).  
 
1.4 Literature review 
This study highlights on four outcomes of ACEIs-drug interactions with interacting 
drugs among cardiac patients. Interacting drugs are: aspirin, thiazide and loop 
diuretics, spironolactone, potassium chloride (KCl) and α-blockers such as prazosin 
and doxazosin. The adverse outcomes are: hyperkalemia, nephrotoxicity, orthostatic 
hypotension and reduced efficacy of ACEIs. Results of this study documented the 
incidences, possible risk factors as well as the probability and severity of such 
events. 
 
1.4.1 Hyperkalemia 
Hyperkalemia is defined as a serious and potentially life-threatening electrolyte 
disorder, following a number of underlying abnormalities in potassium homeostasis 
(Perazella and Mahnensmith, 1997). Hyperkalemia may develop as a complication of 
therapy with ACEIs in patient with one or more of three factors impairing potassium 
excretion such as decreased delivery of sodium to the distal nephron, aldosterone 
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 In chronic heart failure patients, reduction in effective circulatory blood volume leads 
to increase production of renin. This increases activity of angiotensin II, and 
aldosterone promote sodium-water retention that may lead to secondary 
aldosteronism and worsen oedema or hyponatremia and hypokalemia (Saito et al., 
2005). Spironolactone, an aldosterone antagonist has been used as a diuretic or 
antihypertensive agent. When it is used for chronic heart failure patient, it prevents 
the onset of secondary aldosteronism by inhibition of sodium reabsorption and 
potassium excretion in the renal distal tubule and it prevents hypokalemia (Saito et 
al., 2005). 
 
ACEIs lead to lowering the blood pressure by inhibition of angiotensin II and 
consequently aldosterone secretion. ACEIs and spironolactone with potent diuretics 
such as furosemide are commonly used clinically for chronic heart failure patients. 
However, use of ACEIs with spironolactone singly may be associated with 
 21
+ ACEIs with 
spironolactone did not depend on spironolactone dose and might lead to arrhythmia 
and cardiac arrest (Saito et al., 2005). On the other hand, a retrospective study among 
ambulatory patients showed that 72.3% of the patients at risk of hyperkalemia 
associated with spironolactone therapy had serum potassium and creatinine evaluated 
within the study period (Raebel et al., 2007). 
 
Azotemic patients on ACEIs develop elevation of serum potassium by two ways. 
One is when the patient is receiving more than one medication capable of causing 
elevation of potassium level (Chiu et al., 1997), and the other one is the abnormal 
systemic hemodynamic as in chronic heart failure patients may cause severe renal 
vasoconstriction, thus, decrease glomerular filtration rate and tubular flow. In this 
situation elevation of potassium is due to combination of multiple factors  (Garcia et 
al., 2001). Also there are many factors that may contribute to potassium balance in 
renal failure such as urinary flow, fecal excretion and cellular uptake  (Garcia et al., 
2001).  
 
ACEIs play a role in keeping serum potassium levels within normal range, by 
improving insulin sensitivity and changes in intra-cellular potassium distribution 
(Garcia et al., 2001). Likewise, another study suggested that insulin and β -
adrenergic receptors enhanced cellular potassium uptake via increased activity of the 
sodium-potassium-adenosine triphosphatase pump. Consequently, insulin-dependent 
diabetic patients and patients receiving β-blockers are considered to be at high risk 
for hyperkalemia (Obialo et al., 2002). 
2
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Schepkens et al. (2001) study demonstrated that the morbidity and mortality from 
hyperkalemia in certain high-risk patients due to concomitant use of ACE inhibitors 
with spironolactone may outweigh the potential long-term benefits. This result may 
be an evidence for rising incidence of hyperkalemia corresponding to increased 
prescription of spironolactone as potential option in the treatment of heart failure 
patients (Georges et al., 2000). It is worthwhile to note that, RALES reported that the 
use of spironolactone in the treatment of cardiac patients reduced the risk of death 
and hospitalization for all cardiac causes among patients with heart failure due to left 
ventricular systolic dysfunction and using standard therapy including ACE inhibitors. 
The study documented that spironolactone improved symptoms of heart failure and 
had cardioprotective effects (Pitt et al., 1999). In addition, a retrospective study 
conducted in Brazil observed that concomitant use of ACEIs with spironolactone for 
decompensated heart failure patients was associated with severe hyperkalemia. Renal 
impairment and the functional class of CHF were found as significant predictors of 
hyperkalemia in these patients (Cruz et al., 2003).  
 
A study performed to evaluate the usage of spironolactone for severe heart failure 
patients suggested that spironolactone should not be recommended for all patients. 
This coincided with their result that less than 20% of their patients were taking 
spironolactone. This is regardless of clinical evidence which shows that it can 
decrease mortality and hospitalization rates in patients with severe heart failure 
(Trujillo et al., 2004). Notably, the important features of patients who develop 
hyperkalemia due to the use of spironolactone with ACEIs include advanced age and 
concurrent use of other drugs responsible for elevation of serum potassium such as 
potassium-sparing diuretics, potassium supplements, NSAIDs or cyclooxygenase 
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 Population-based time series study conducted in Ontario suggested that the rate of 
prescription of spironolactone for elderly patients on ACE inhibitors therapy 
increased greatly after publication of RALES (Juurlink et al., 2004). Moreover, they 
observed increases in rates of hospitalization for hyperkalemia associated with 
increase in morbidity and mortality rate (Juurlink et al., 2004). 
 
A case series study observed that there are certain factors that lead to the 
development of severe hyperkalemia in patients with heart failure treated with 
spironolactone and ACE inhibitors or AT1 receptor blockers; advanced age, dose of 
spironolactone more than 25 mg/day, insufficient renal function and diabetes mellitus 
type-2. The investigators suggested that undetected hyperkalemia may be the 
possible cause for sudden death in some heart failure patients (Wrenger et al., 2003). 
Whereas, a study carried out among heart failure outpatients using spironolactone 
found that elderly patients with decreased left ventricular ejection fraction (≤ 20%) 
and higher NYHA class were considered to be at higher risk for hyperkalemia 
(Svensson et al., 2004). 
 
A case-control study performed in Buffalo showed that the risk of hyperkalemia in 
chronic heart failure patient was not only related to concomitant use of 
spironolactone with ACE inhibitors but other risk factors independently associated 
with hyperkalemia such as diabetes mellitus and impaired renal function (Ramadan 
et al., 2005). 
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